The company said that diagnostic testing volumes, product and royalty revenues, and clinical services revenues all fell year over year.
The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.
The investment bank called Genomic Health a leader in diagnostic testing and said Invitae will benefit from growth trends in the genetic testing sector.
The firm said clinical services revenues fell during the quarter due to reduced insurance reimbursement payments and mix of testing in the prior year.
As part of the deal, which is worth at least $3 million for the first five years, Primerdesign will develop and supply 384-well plate molecular assay panels for Genesis.
The firm missed the Wall Street estimates on the top and bottom lines, and it lowered its EPS and adjusted EPS guidance for full-year 2018.
The firm said the decline in Q4 revenues was due to an account loss as well as lower insurance reimbursement and shifts away from high-value genetic testing.
The assets include significant genetic data related to women's diseases and degenerative disc disease, which Predictive will use to develop gene-based diagnostics.
The lab created active molecular identification tags to be able to track specimens themselves, rather than just their containers.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.
Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.
New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.
In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.